Evidence map›Paper›PMID 38503969›Full record

ArticleVirchows Archiv : an international journal of pathology2024

Utility of LEF1 to differentiate desmoid fibromatosis from its histologic mimics.

Soma Jobbagy, Santiago Lozano-Calderon, John T Mullen, G Petur Nielsen, Yin P Hung, Ivan Chebib

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Soma JobbagyDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, WRN2, 55 Fruit St, Boston, MA, 02114, USA.ORCID https://orcid.org/0000-0002-6242-5595
Santiago Lozano-CalderonDepartment of Orthopedic Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.ORCID https://orcid.org/0000-0002-0681-9004
John T MullenDepartment of Surgical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
G Petur NielsenDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, WRN2, 55 Fruit St, Boston, MA, 02114, USA.ORCID https://orcid.org/0000-0002-9671-7211
Yin P HungDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, WRN2, 55 Fruit St, Boston, MA, 02114, USA.ORCID https://orcid.org/0000-0002-8568-1591
Ivan ChebibDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, WRN2, 55 Fruit St, Boston, MA, 02114, USA. ichebib@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-6826-0226
Harvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diagnosis of desmoid-type fibromatosis (DF) may be challenging on biopsy due to morphologic overlap with reactive fibrosis (scar) and other uniform spindle cell neoplasms. Evaluation of nuclear β-catenin, a surrogate of Wnt pathway activation, is often difficult in DF due to weak nuclear expression and high background membranous/cytoplasmic staining. Lymphoid enhancer-factor 1 (LEF1) is a recently characterized effector partner of β-catenin which activates the transcription of target genes. We investigated the performance of LEF1 and β-catenin immunohistochemistry in a retrospective series of 156 soft tissue tumors, including 35 DF, 3 superficial fibromatosis, and 121 histologic mimics (19 soft tissue perineurioma, 8 colorectal perineurioma, 4 intraneural perineurioma, 26 scars, 23 nodular fasciitis, 6 low-grade fibromyxoid sarcomas, 6 angioleiomyomas, 5 neurofibromas, 5 dermatofibrosarcoma protuberans, 3 low-grade myofibroblastic sarcomas, 3 synovial sarcomas, 3 inflammatory myofibroblastic tumors, 2 schwannomas, and 1 each of Gardner-associated fibroma, radiation-associated spindle cell sarcoma, sclerotic fibroma, dermatofibroma, and glomus tumor). LEF1 expression was not only seen in 33/35 (94%) of DF but also observed in 19/23 (82%) nodular fasciitis, 7/19 (37%) soft tissue perineurioma, 2/3 (66%) synovial sarcoma, and 6/26 (23%) scar, as well as in 1 radiation-associated spindle cell sarcoma. The sensitivity and specificity of LEF1 IHC for diagnosis of DF were 94% and 70%, respectively. By comparison, β-catenin offered similar sensitivity, 94%, but 88% specificity. Positivity for LEF1 and β-catenin in combination showed sensitivity of 89%, lower than the sensitivity of β-catenin alone (94%); however, the combination of both LEF1 and β-catenin improved specificity (96%) compared to the specificity of β-catenin alone (88%). Although LEF1 has imperfect specificity in isolation, this stain has diagnostic utility when used in combination with β-catenin.

Indexed as

beta CateninBiomarkers, TumorDesmoid TumorsImmunohistochemistryLymphoid Enhancer-Binding Factor 1Soft Tissue NeoplasmsDiagnosis, DifferentialFemaleHumansMaleRetrospective Studiesbeta CateninBiomarkers, TumorCTNNB1 protein, humanLEF1 protein, humanLymphoid Enhancer-Binding Factor 1Desmoid-type fibromatosisImmunohistochemistryLEF1Wnt pathwayβ-catenin

Identifiers

PMID38503969
OpenAlexW4392970402

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.